Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
Shinnosuke FujiwaraTakeo KosakaYoshinori NishimotoKen KamisawaKeitaro WatanabeYuto BabaToshikazu TakedaKazuhiro MatsumotoMototsugu OyaPublished in: The Prostate (2023)
Serum testosterone level may be a prognostic marker for cabazitaxel therapy in patients with mCRPC who are younger than 70 years, and high serum testosterone levels may lead to longer survival.
Keyphrases